associations as well as the precision are not reported in the results and barely discussed in the discussion. I believe the reader would benefit from this data to better grasp the strength of associations between comorbidities and mortality. • The results section has only but a small mention of the ROB evaluation (P.13 line 15) . A section with more information in regards to the types of biases and methodological issues encountered should be added. • Table 1 : Study entry varies from study to another. In some studies, patients are followed from ICU admission whereas other from rehabilitation unit discharge. I believe this information needs to be added as it likely influences study results.
Minor comments: • P.8 line 8 -There is a misplaced period at the end of the line after "and." • P.8 line 18-19 . The sentence which starts with "Over 200 per 100,000 individuals" seems repetitive with the previous sentence. Please review. • P.8 line 27 . What is the difference between a restriction and a limitation? • P.11 line [8] [9] [10] . Consider modifying this sentence as it is long and unclear. • P.13 line 50. The outcome of focus in the SR is all-cause mortality. Why was a study measuring cardiovascular mortality included? Does this follow the PICO? • P.15 line 7-9. Were these associations evaluated in adjusted multivariate analyses? • P.15 line Line 12-18. MVA, falls and violence were associated with an increase in mortality compared to what other mechanisms? • P.16 line 4-15. Were these mental health disorders measured prior to the TBI or were they a complication of the TBI? The same comment applies to stroke, epilepsy and cardiovascular diseases. This will likely have an impact on the reported associations. Could the authors comment on this and add the information to the results? • P.16 line 52. Stress hyperglycemia is a physiologic response to stress and not necessarily diabetes. Hyperglycemia is a marker of disease severity and different from chronic diabetes. I would refrain form considering these two states as a single and same comorbidity. • P.18 line 3. Given the important differences in study methods between the studies, a discussion in regards to optimal methods and influence on outcomes is warranted. • P.18 line 24. In these studies of comorbidity scores and outcome, were the comorbidities always measured prior to the TBI? Please • P.18 line 31-33. Considering death rates among the general population when examining the influence of TBI is effectively a very important point. Highlighting the studies that adjusted for death rates in the general population in the tables or results would be interesting. • P.18 line 36-38. Are there any methodological differences between the included studies which would explain why sex and gender show mixed associations with mortality? • P.18 line 47. Plausible (or possible?) to determine the effects of these socio-demographic variables... P.21 line 12. Pre-existing epilepsy or post traumatic epilepsy? P.21 line 23. Pre-existing stroke or TBI induced? P.21 line 34. Is liver failure a circulatory system disorder? P.22 line 54. Stress hyperglycemia is a marker of disease severity. An alternative hypothesis would be that hyperglycemia is associated with worse disease and thus increased mortality, regardless of According to the wide-versa of TBI condition, authors "first-of-it-kind" review is much appreciated and so appraised for demonstrating the future path on studies' design. This was a peer-systematic-review and hope the further studies obtain its recommendations for their work design proposal. Response: Thank you so much for taking time to review and provide comments on our manuscript.
Reviewer: 2 Reviewer Name: David Williamson Institution and Country: Université de Montreal Sacré-Coeur Hospital, Canada Please state any competing interests or state "None declared": None declared
The authors have conducted a SR of a great number of studies. They have managed to clearly synthesize the information in a number of massive tables. The results are quite interesting and pertinent for future studies on the subject. Response: Thank you very much for your comments.
Major comments:
• The authors need to be clearer in the methods about how they proceeded to exclude the 29 studies deemed of low quality. How was this determined? The supplement does give reasons for exclusion but how did the authors determine which and how many biases were important enough to merit exclusion. Given the very large number of studies excluded, this process likely has an important impact of the reported findings and increases the risk of reporting bias. Response: The Methods section pertaining to the Risk of Bias Assessment (Page 12) has been edited to expand Risk of Bias section. It now reads: The quality of each study was evaluated independently by two reviewers (CX and SH) using the Quality in Prognosis Studies (QUIPS) tool to assess risk of bias in studies of prognostic factors.20
The assessment of each study quality consisted of the following steps: (i) assessment of seven categories of potential bias sources including study participation, study design, study attrition, prognostic factor, outcome measurements, confounding measurement and account as well as analyses; (ii) grading the presence of potential biases in each category as "Yes," "Partly," "No," or "Unsure", and (iii) summarizing the overall level of potential bias for each study where "++" was assigned when all seven quality criteria were fulfilled (allowing one "Partly" in each bias category); "+" was assigned when four to six criteria were fulfilled; "−" was assigned when fewer than four criteria were fulfilled (i.e., at least one "Yes" in each category). A retrospective cohort study design is weaker than a prospective, and therefore "++" rating (if achieved) was degraded to "+". Studies assigned "++" were referred to as "high quality studies", studies assigned "+" were referred to as "moderate quality studies" and studies assigned "-" were referred to as "low quality studies". Details on the process of quality assessment are presented in a data Supplementary Tables 1 and 2 . Disagreements between the two reviewers were mediated by a third reviewer (TM), who assessed the study"s quality independent of the two reviewers and followed-up with a discussion between researchers.
• Did the authors measure statistical heterogeneity before ruling out meta-analysis? Response: Due to the wide range of populations studied, forms and types of comorbidities examined and the mortality outcome, we were unable to identify at least two similar studies that address the same outcome measured the same way, using the same approach to statistical analysis, to be fitting criteria for a meta-analysis. We refer the reader to Table 1 for specifics. • The search strategy is more than one year old. I suggest an update to include studies published since May 2017. Response: We anticipated concern about the need to perform updated search strategy and edited our searches on January 17, 2019. The PRISMA diagram has been edited accordingly. Updated searches are presented in Supplementary file 1. Edited searches identified one additional study, which was not included in the systematic review due to low study quality. Relevant changes were made throughout the manuscript.
• Although reported in supplementary table 2, strengths of reported associations as well as the precision are not reported in the results and barely discussed in the discussion. I believe the reader would benefit from this data to better grasp the strength of associations between comorbidities and mortality. Response: The magnitude of relative risk, hazard ratio (and other appropriate effect sizes), unadjusted and adjusted, with confidence intervals, are presented in Table 1 . Significance of each comorbidity"s association with mortality has been depicted in Supplementary Table 4 . In response to reviewer comment, we added to the manuscript that effect sizes varied greatly and referred the reader to Table 1 for specifics. The discussion of these relationships has also taken into account the strength of these associations.
• The results section has only but a small mention of the ROB evaluation (P.13 line 15) . A section with more information in regards to the types of biases and methodological issues encountered should be added. Response: A paragraph highlighting the methodologies used to ascertain comorbidities has been added to the Discussion section (Page 25) to address this concern, which now reads:
The study results depend on the quality of included studies, of which none were high quality based on the risk of bias assessment. Included studies were frequently penalized for being retrospective cohort studies, incomplete or no reporting on missing data, and limited reporting on power calculation and statistical analysis. Although most studies performed some form of adjustment for confounders, this was often not described in detail. Most studies did not account for severity of the comorbidity under study, or whether or not the studied comorbidity was adequately controlled by medication, remained untreated, or was treatment-resistant. In addition, many studies did not control for TBI severity. The lack of consistency in variables included in the modelling process (Table 1 ) and details about independency between included variables (i.e., risk factors studied), were among main methodological issues we encountered. this information directly, as they measured comorbidity at the baseline assessment from which a follow-up started. All studies reported on comorbidity on the time of admission due to TBI, which indicated that the comorbidity did not have time to develop, unless comorbidity was a concurrent to TBI (i.e., other trauma, including spinal cord injury). In our results, we reported on comorbidity present at the baseline assessment, as it affected mortality outcome and reported by authors. We have edited the Limitations section (Page 27) to address this concern. • P.16 line 52. Stress hyperglycemia is a physiologic response to stress and not necessarily diabetes. Hyperglycemia is a marker of disease severity and different from chronic diabetes. I would refrain from considering these two states as a single and same comorbidity. Response: Thank you for your suggestion. We made edits to the Results section (Page 18) and Supplementary tables 3 and 4 accordingly.
• P.18 line 3. Given the important differences in study methods between the studies, a discussion in regards to optimal methods and influence on outcomes is warranted. Response: A paragraph highlighting the methodologies used to ascertain comorbidities has been added to the Discussion section (Page 26) to address this concern, which now reads: Closer examination of discrepancies between studies" results revealed a methodological difference between studies that observed a significant and non-significant association. To elaborate, most studies that employed administrative databases did not establish a significant association between psychiatric disorders and mortality27 40 while most studies that used medical records did.22 43 While administrative data had previously been found to agree with medical records for recording of comorbidities, there is a tendency for under-reporting of comorbid conditions in administrative data.61 As such, the association between comorbidities and mortality can be potentially masked by the reporting discrepancy. Together, these methodological inconsistencies among studies examined preclude conclusive inferences on the role of comorbidities on post-TBI mortality. Future efforts in this field can focus on performing in-depth examinations of these relationships in order to substantiate evidence, which can inform decision-making and planning of healthcare strategies tailored for TBI patients with these comorbid conditions. • P.18 line 24. In these studies of comorbidity scores and outcome, were the comorbidities always measured prior to the TBI? Please Response: Please see our response to the above comment (P.16 line 4-15).
• P.18 line 31-33. Considering death rates among the general population when examining the influence of TBI is effectively a very important point. Highlighting the studies that adjusted for death rates in the general population in the tables or results would be interesting. Response: Among all the studies that examined post-TBI mortality, only a single study took into account the death rates among the general population and the findings of this study have been highlighted in the Discussion section (Page 20)
• P.18 line 36-38. Are there any methodological differences between the included studies which would explain why sex and gender show mixed associations with mortality? Response: Review of the included studies did not find any methodological differences between studies that found and did not find significant associations between sex and gender and mortality.
• P.18 line 47. Plausible (or possible?) to determine the effects of these socio-demographic variables... Response: The word "plausible" has been replaced with "possible" (Page 20). P.21 line 12. Pre-existing epilepsy or post traumatic epilepsy? Response: Please see our response to the above comment (P.16 line 4-15) .
